ACXP — Acurx Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Acurx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 13 | 9.11 | 7.47 | 3.71 | 7.56 |
| Net Total Receivables | — | — | 0.129 | 0.051 | 0.048 |
| Prepaid Expenses | |||||
| Total Current Assets | 13.3 | 9.38 | 7.71 | 3.86 | 7.69 |
| Total Assets | 13.3 | 9.38 | 7.71 | 3.86 | 7.69 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 0.844 | 2.06 | 3.04 | 3.24 | 2.42 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.844 | 2.06 | 3.04 | 3.24 | 2.42 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 12.4 | 7.32 | 4.67 | 0.615 | 5.27 |
| Total Liabilities & Shareholders' Equity | 13.3 | 9.38 | 7.71 | 3.86 | 7.69 |
| Total Common Shares Outstanding |